Peripheral T-Cell Lymphoma Epidemiology Forecast till 2030

July 17 13:48 2020
Peripheral T-Cell Lymphoma Epidemiology Forecast till 2030

DelveInsight
DelveInsight’s ‘Peripheral T-Cell Lymphoma (PTCL) Epidemiology Forecast–2030’ report delivers an in-depth understanding of the disease, historical and forecasted PTCL epidemiology in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), and Japan.

Peripheral T-Cell Lymphoma (PTCL) is a diverse group of aggressive lymphomas that develop from mature T-cells and natural killer (NK) cells.

 

Key Highlights from Peripheral T-Cell Lymphoma report:-

·         PTCL accounts for 10–15% of all non-Hodgkin lymphomas worldwide.

·         The total incident population of Peripheral T-Cell Lymphoma (PTCL) in 7MM in 2017- 16,298

·         The incident population of PTCL in 2017

Ø  The United States – 6,110

Ø  Germany – 1,183

 

Ø  UK – 1,100 

·         PTCL is categorized into four stages based on the area affected and incident cases in the United States in 2017:-

Ø  Stage I – 876

Ø  Stage II – 727

Ø  Stage III – 1,434

Ø  Stage IV  – 3,074

·         The incident cases of PTCL in the United States in year 2017

Ø  PTCL-Not-Otherwise Specified (PTCL-NOS) accounts for 31% of all incident cases of PTCL

 

Ø  Anaplastic Large Cell Lymphoma (ALCL) accounts for 26% of all incident cases of PTCL

 

Scope of the Report:-

 The report covers the descriptive overview of PTCL, explaining its causes, signs and symptoms, and pathophysiology.

 The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan.

 The report assesses the disease risk and burden.

 The report provides the segmentation of the disease epidemiology for 7MM by Total Incident Cases of PTCL, Stage-specific Incident Cases of PTCL, and Subtype-specific Incident Cases of PTCL.

 

Request for sample pages

 

Table of contents 

1. Key Insights

 

2. Executive Summary of Peripheral T-cell Lymphoma (PTCL)

 

3. Disease Background and Overview: Peripheral T-cell Lymphoma (PTCL)

 

3.1. Introduction

 

3.2. Classification of PTCL

 

3.2.1. WHO Classification System

 

3.3. Subtypes of PTCL

 

3.3.1. Peripheral T-Cell Lymphoma, Not Otherwise Specified (PTCL-NOS)

 

3.3.2. Anaplastic Large Cell Lymphoma (ALCL)

 

3.3.3. Angioimmunoblastic T-Cell Lymphoma (AITL)

 

3.4. Signs and Symptoms

 

3.5. Cause of PTCL

 

3.6. Pathophysiology

 

3.7. Other conditions that can mimic PTCL

 

3.8. Staging

 

3.9. Diagnosis

 

3.9.1. Blood tests

 

3.9.2. Diagnostic Scans

 

4. PTCL Epidemiology and Patient Population

 

4.1. Key Findings

 

4.2. KOL Views

 

4.3. PTCL Epidemiology Methodology

 

4.4. Total Incident Cases of Peripheral T-cell Lymphoma (PTCL) in the 7MM

 

5. United States Epidemiology

 

5.1. Assumptions and Rationale

 

5.2. Total Incident Cases of Peripheral T-cell Lymphoma (PTCL) in the United States

 

5.3. Stage-specific Incident Cases of Peripheral T-cell Lymphoma (PTCL) in the United States

 

5.4. Subtype-specific Incident cases of Peripheral T-cell Lymphoma (PTCL) in the United States

 

6. EU5 Epidemiology

 

6.1. Assumptions and Rationale

 

6.2. Germany Epidemiology

 

6.2.1. Total Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Germany

 

6.2.2. Stage-specific Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Germany

 

6.2.3. Subtype-specific Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Germany

 

6.3. France Epidemiology

 

6.3.1. Total Incident Cases of Peripheral T-cell Lymphoma (PTCL) in France

 

6.3.2. Stage-specific Incident Cases of Peripheral T-cell Lymphoma (PTCL) in France

 

6.3.3. Subtype-specific Incident Cases of Peripheral T-cell Lymphoma (PTCL) in France

 

6.4. Italy Epidemiology

 

6.4.1. Total Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Italy

 

6.4.2. Stage-specific Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Italy

 

6.4.3. Subtype-specific Diagnosed Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Italy

 

6.5.1. Total Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Spain

 

6.5.2. Stage-specific Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Spain

 

6.5.3. Subtype-specific Diagnosed Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Spain

 

6.6. United Kingdom Epidemiology

 

6.6.1. Total Incident Cases of Peripheral T-cell Lymphoma (PTCL) in the UK

 

6.6.2. Stage-specific Incident Cases of Peripheral T-cell Lymphoma (PTCL) in the UK

 

6.6.3. Subtype-specific Diagnosed Incident Cases of Peripheral T-cell Lymphoma (PTCL) in the UK

 

7. Japan Epidemiology

 

7 .1. Assumptions and Rationale

 

7.2. Total Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Japan

 

7.3. Stage-specific Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Japan

 

7.4. Subtype-specific Diagnosed Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Japan

 

8. Recognized Establishments

 

9. Appendix

 

9.1. Bibliography

 

9.2. PTCL Report Methodology

 

10. DelveInsight Capabilities

 

11. Disclaimer

 

12. About DelveInsight

 

·         Peripheral T-Cell Lymphoma (PTCL) is a diverse group of aggressive lymphomas that develop from mature T-cells and natural killer (NK) cells.

 

Media Contact
Company Name: DelveInsight
Contact Person: Priya Maurya
Email: Send Email
Phone: +919650213330
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

  Categories: